INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 October 2017
Net Assets |
£231m |
Net Assets per share |
616p |
Share price |
600p |
Total value of unquoted investments |
£21m |
Total number of portfolio companies |
90 |
Dividend |
4% of NAV per annum |
Top Ten Quoted Investments
Company Name |
% NAV |
Biogen |
7.3 |
Celgene |
5.9 |
Regeneron |
5.4 |
Vertex |
4.2 |
Exelixis |
3.6 |
Adamas |
3.5 |
Incyte |
3.3 |
Gilead |
3.0 |
Alexion |
3.0 |
Acadia |
2.7 |
|
----------- |
Total |
41.9 |
Geographical Allocation |
% NAV |
US & Canada |
89 |
Europe & UK |
11 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
91 |
Unquoted |
9 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
41 |
Mid Cap =USD1-10BN |
27 |
Small Cap <USD1BN |
32 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
35 |
Rare diseases |
13 |
CNS |
12 |
Inflammation |
9 |
Ophthalmology |
8 |
Infectious Diseases |
6 |
Metabolic |
6 |
Medtech |
2 |
Other |
9 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
27 NOVEMBER 2017